RSS | Login | Register

CEPROTIN

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare CEPROTIN to:

Generic Name for CEPROTIN

Protein C concentrate (human) 500 IU, 1000 IU; per vial; lyophilized pwd for IV inj after reconstitution; contains albumin; preservative-free.

Legal Classification:

Pharmacological Class for CEPROTIN

Anticoagulant protein.

Manufacturer of CEPROTIN

Baxter

Indications for CEPROTIN

Prevention and treatment of venous thrombosis and purpura fulminans. Replacement therapy for pediatric and adult patients.

Adults and Children:

<10kg: max infusion rate 0.2mL/kg/min; ≥10kg: max infusion rate 2mL/min. Individualize. Acute episodes/short term prophylaxis: initially 100–120 IU/kg, then 60–80 IU/kg every 6 hours for 3 doses (adjust dose to maintain target peak protein C activity of 100%); maintenance: 45–60 IU/kg every 6 or every 12 hours (maintain trough protein C level above 25% for duration of therapy); continue until desired anticoagulation achieved. Long-term prophylaxis: 45–60 IU/kg every 12 hours (maintain trough protein C level above 25%). Switching to oral anticoagulants: start with low dose; continue protein C replacement until stable anticoagulation obtained.

Warnings/Precautions for CEPROTIN

Measure protein C activity before and during treatment; if acute thrombotic event occurs, obtain protein C activity measurement before the next injection until patient is stable. Contains human plasma; monitor for possible infection transmission. Mouse protein allergy. Contains heparin; if heparin-induced thrombocytopenia suspected, check platelet counts immediately, consider discontinuing. Renal impairment and/or sodium-restricted (max daily dose contains sodium >200mg). Pregnancy (Cat.C). Nursing mothers.

Interactions for CEPROTIN

Increased risk of bleeding with concurrent anticoagulants, tissue plasminogen activator.

Adverse Reactions for CEPROTIN

Rash, itching, lightheadedness; hypersensitivity reactions (discontinue if occurs); hemothorax, hypotension.

Notes for CEPROTIN

Report all infections suspected to be transmitted by Ceprotin to (866) 888-2472.

How is CEPROTIN supplied?

Single-use vial—1 (w. diluent, supplies)

Related Disease:

Protein C deficiency

FDA warns of medication errors with nimodipine oral capsules

August 02, 2010

The FDA is reminding healthcare professionals that oral nimodipine capsules should be given only by mouth or through a nasogastric tube and should never be given by intravenous administration.

Generic Lovenox approved for anticoagulation

July 26, 2010

The FDA has granted Sandoz approval of a generic version of Lovenox (enoxaparin sodium injection, from sanofi aventis).

Coumadin 1mg tablet blister packs recalled

July 14, 2010

Bristol-Myers Squibb announced a voluntary recall of several lots of Coumadin (warfarin sodium) 1mg tablet blister packs.

Sagent Pharmaceuticals' heparin sodium injection approved

July 01, 2010

The FDA has approved nine presentations of heparin sodium injection from Sagent Pharmaceuticals.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.